2-(Phenylthio)ethyl formate | 91228-20-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(Phenylthio)ethyl formate
• 英文别名: β-(phenylthio)ethyl formate；formic acid 2-phenylsulfanylethyl ester；2-Phenylsulfanylethyl formate
• CAS: 91228-20-5
• 化学式: C₉H₁₀O₂S
• 分子量: 182.243
• InChiKey: VCNHQBYKUDIUHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(Phenylthio)ethyl formate 在 对苯二酚 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 11.0h， 生成 1-[4-Methyl-2-(2-phenylsulfanyl-ethoxy)-cyclohex-3-enyl]-ethanone
  参考文献：
  名称：

  Synthesis and highly regioselective Diels-Alder reaction of functionalized isoprenes involving a terminal alkoxy group and chemical modification of the resulting adducts

  摘要：

  DOI：

  10.1021/jo00193a028
• 作为产物：
  描述：

  2,2'-[1,2-ethanediylbis(oxy)]-bis-1,3-dioxolane 、 苯基硫三甲基硅烷 在 三氟甲磺酸三甲基硅酯 作用下， 反应 0.5h， 以48%的产率得到2-(Phenylthio)-1,3-dioxolane
  参考文献：
  名称：

  (Dialkoxymethyl)lithiums: generation, stability, and synthetic transformations

  摘要：

  DOI：

  10.1021/ja00186a036

文献信息

• Mild and Highly Selective Formyl Protection of Primary Hydroxyl Groups
  作者：Lidia De Luca、Giampaolo Giacomelli、Andrea Porcheddu

  DOI：10.1021/jo0257492

  日期：2002.7.1

  Efficient conversion of primary alcohols to the corresponding formate esters can be carried out at room temperature in methylene chloride, using 2,4,6-trichloro-1,3,5-triazine and N,N-dimethylformamide in the presence of lithium fluoride. This procedure appears as a valid method for selectively protecting primary hydroxyl groups.

  可以在室温下在二氯甲烷中，在氟化锂的存在下，使用2,4,6-三氯-1,3,5-三嗪和N，N-二甲基甲酰胺在二氯甲烷中将伯醇有效转化为相应的甲酸酯。该程序似乎是选择性保护伯羟基的有效方法。
• [EN] RELEASABLE CONJUGATES<br/>[FR] CONJUGUÉS LIBÉRABLES
  申请人：QUIAPEG PHARMACEUTICALS AB

  公开号：WO2018163131A1

  公开（公告）日：2018-09-13

  The present application provides compounds of Formula (B), or pharmaceutically acceptable salts thereof, wherein D is a residue of a biologically active drug, which underdo hydrolysis under physiological conditions to release the biologically active drug and which are useful in the treatment of disorders that could be beneficially treated with the drug.

  本申请提供了化合物的公式（B），或其药用盐，其中D是生物活性药物的残留物，在生理条件下经过水解释放出生物活性药物，并且对可能受益于该药物治疗的疾病具有用处。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0000644A2

  公开（公告）日：1979-02-07

  Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions. Lower cycloalkyl substituted-benzene derivatives of the formula:- wherein R' is lower cycloalkyl, R2 is carboxy, esterified carboxy, hydroxymethyl, lower alkoxymethyl or acyloxymethyl, R3 is lower alkanoyl or lower alkyl substituted with hydroxy, amino, lower alkylamino, di(lower)alkylamino, acylamino, lower alkoxy, acyl or acyloxy, in which the lower alkyl moieties of the di(lower)alkyl amino radical may be joined together to form a heterocyclic ring containing the nitrogen atom and the carbonyl function of the acyl radical, which is a substituent on the lower alkyl radical, may be protected, X is hydrogen or halogen, and Y is a valency bond or lower alkylene; and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising the same; and methods for treatment of inflammation by administering the same to mammals.

  下环烷基取代苯衍生物、其制备方法及其药物组合物。 式中的低级环烷基取代苯衍生物：- 低级环烷基取代苯衍生物 其中 R' 是低级环烷基、 R2 是羧基、酯化羧基、羟甲基、低级烷氧基甲基或酰氧基甲基、 R3是低级烷酰基或被羟基、氨基、低级烷基氨基、二（低级）烷基氨基、酰氨基、低级烷氧基、酰基或酰氧基取代的低级烷基，其中二（低级）烷基氨基的低级烷基可连接在一起形成含氮原子的杂环，酰基的羰基功能（低级烷基上的取代基）可被保护、 X 是氢或卤素，以及 Y 是价键或低级亚烷基； 及其药学上可接受的盐类； 包含上述物质的药物组合物；以及通过对哺乳动物施用上述物质治疗炎症的方法。
• Process for producing a heterocyclic tertiary amine
  申请人：NISSAN CHEMICAL INDUSTRIES LTD.

  公开号：EP0516982A1

  公开（公告）日：1992-12-09

  A process for producing a heterocyclic tertiary amine of the formula (III): wherein A is a nitrogen atom or C-R⁵, B is a nitrogen atom or C-R⁶, ---- is a single bond or a double bond, and each of R¹, R², R³, R⁴, R⁵ and R⁶ which may be the same or different, is a hydrogen atom , an acyl group, a halogen atom, a cyano group, etc., provided that two of R¹, R², R³ and R⁴ may together form a 3-membered, 4-membered, 5-membered or 6-membered aliphatic ring, a heterocyclic ring or aromatic ring, and R⁷ is a C₁₋₆ alkyl group which may be substituted, etc., which process comprises reacting a heterocyclic secondary amine of the formula (I): wherein A, B, ----, R¹, R², R³ and R⁴ are as defined above, with an alkylating agent of the formula (II):         R⁷-X   (II) wherein R⁷ is as defined above, and X is a hydroxyl group, a halogen atom, a OSO₃R⁷ group, a OSO₂R⁷ group, a OCO₂R⁷ group, a OCOR⁷ group, a OP(O)(OR⁷) group, a OP(O)O(R⁷)₂ group or an amino group, in the presence of a catalyst of Group VIII of the Periodic Table.

  一种生产式 (III) 的杂环叔胺的工艺： 其中 A 是氮原子或 C-R⁵，B 是氮原子或 C-R⁶，---- 是单键或双键，R¹、R²、R³、R⁴、R⁵ 和 R⁶ 中的每一个可以相同或不同，是氢原子、酰基、卤素原子、氰基等、但 R¹、R²、R³ 和 R⁴ 中的两个可共同形成 3 元、4 元、5 元或 6 元脂族环、杂环或芳香环，且 R⁷ 是可被取代的 C₁₋₆烷基等，该过程包括使式 (I) 的杂环仲胺发生反应： 其中 A、B、----、R¹、R²、R³ 和 R⁴ 如上定义，与式 (II) 烷基化剂反应： R⁷-X (II) 其中 R⁷ 如上定义，X 是羟基、卤素原子、OSO₃R⁷ 基团、OSO₂R⁷ 基团、OCO₂R⁷ 基团、OCOR⁷基团、OP(O)(OR⁷)基团、OP(O)O(R⁷)₂基团或氨基。